In situ mass spectrometry of autoimmune liver diseases.
Primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH) are the major forms of autoimmune liver diseases each characterized by the destruction of a specific liver cell type and the presence of differing auto-antibodies. We took a proteomic approach utilizing in situ matrix-assisted laser desorption/ionization mass spectrometry (MALDI MS) to obtain profiles directly from liver samples of patients with PBC, PSC, AIH and controls. The ability to precisely localize the region for acquisition of MALDI MS allowed us to obtain profiles from bile ducts, inflammatory infiltrates and hepatocytes from each biopsy sample. Analysis tools developed to identify peaks and compare peaks across diseases and cell types were used to develop models to classify the samples. Using an initial set of testing samples from PBC patients and controls, we identified unique peaks present in bile ducts, inflammatory infiltrates and hepatocytes that could classify samples in a validation cohort with 88-91% accuracy. Interestingly, profiles of PSC and AIH did not differ significantly from PBC. Identification of proteins in these peaks may represent novel autoantigens or effector molecules. These findings illustrate the potential of a proteomic approach to autoimmune diseases with in situ MALDI MS.
Division of Gastroenterology and Hepatology, University of California, Davis, CA, USA. clbowlus@ucdavis.edu
Christopher L
CL
Bowlus
Erin H
EH
Seeley
Joanna
J
Roder
Julia
J
Grigorieva
Heinrich
H
Roder
Richard M
RM
Caprioli
Meric
M
Gershwin
D001323:Autoantibodies / Q000097:blood; D015209:Cholangitis, Sclerosing / Q000175:diagnosis / Q000276:immunology / Q000378:metabolism; D020869:Gene Expression Profiling; D019693:Hepatitis, Autoimmune / Q000175:diagnosis / Q000276:immunology / Q000378:metabolism*; D022781:Hepatocytes / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D008099:Liver / Q000276:immunology / Q000473:pathology; D008105:Liver Cirrhosis, Biliary / Q000175:diagnosis / Q000276:immunology / Q000378:metabolism*; D013058:Mass Spectrometry; D040901:Proteomics; D015203:Reproducibility of Results
D001323:Autoantibodies
Clin Cancer Res. 2010 Jan 15;16(2):681-90
20068102
Electrophoresis. 1997 Mar-Apr;18(3-4):533-7
9150937
Autoimmun Rev. 2006 Aug;5(7):449-57
16920571
J Proteome Res. 2008 Apr;7(4):1500-7
18386930
Lancet. 2003 Aug 9;362(9382):433-9
12927430
Semin Immunopathol. 2009 Sep;31(3):383-97
19468733
J Gastroenterol. 2008;43(11):866-74
19012040
Clin Cancer Res. 2006 Sep 1;12(17):5142-50
16951232
Curr Opin Biotechnol. 2006 Aug;17(4):431-6
16781865
Mol Cell Proteomics. 2006 Oct;5(10):1975-83
16849436
Autoimmun Rev. 2005 Jun;4(5):315-21
15990080
Hepatology. 2007 Mar;45(3):659-65
17326160
Cell Mol Immunol. 2010 Jan;7(1):1-10
20029462
J Proteome Res. 2006 Nov;5(11):2889-900
17081040
Am J Gastroenterol. 2005 Sep;100(9):2019-30
16128947
Clin Dev Immunol. 2006 Jun-Dec;13(2-4):265-71
17162367
Liver Int. 2008 Aug;28(7):997-1010
18422935
J Autoimmun. 2009 May-Jun;32(3-4):246-53
19345069